560 related articles for article (PubMed ID: 11022130)
1. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
2. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
3. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
5. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
7. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
8. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
[TBL] [Abstract][Full Text] [Related]
10. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
12. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.
Robak E; Sysa-Jedrzejowska A; Stepień H; Robak T
Eur Cytokine Netw; 1997 Sep; 8(3):281-6. PubMed ID: 9346362
[TBL] [Abstract][Full Text] [Related]
13. IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients.
Stelmasiak Z; Kozioł-Montewka M; Dobosz B; Rejdak K
Med Sci Monit; 2001; 7(5):914-8. PubMed ID: 11535934
[TBL] [Abstract][Full Text] [Related]
14. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
15. Cytokines in patients with ischaemic heart disease or myocardial infarction.
Bossowska A; Kiersnowska-Rogowska B; Bossowski A; Galar B; Sowiński P
Kardiol Pol; 2003 Aug; 59(8):105-14. PubMed ID: 14560325
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
[TBL] [Abstract][Full Text] [Related]
17. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.
Usón J; Balsa A; Pascual-Salcedo D; Cabezas JA; Gonzalez-Tarrio JM; Martín-Mola E; Fontan G
J Rheumatol; 1997 Nov; 24(11):2069-75. PubMed ID: 9375862
[TBL] [Abstract][Full Text] [Related]
18. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic activity in multiple myeloma.
Yağci M; Sucak GT; Haznedar R
Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
[TBL] [Abstract][Full Text] [Related]
20. [A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy].
Tang L; Luo Q; Zhou X; Xia R
Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):165-7. PubMed ID: 11955323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]